Details of the Drug

General Information of Drug (ID: DMIEPJG)

Drug Name
BTT-1023
Synonyms
SI-3106; SI-636; Fully human VAP-1 mAbs (inflammation), BioTie/Seikagaku; Fully human VAP-1 monoclonal antibody (inflammation), BioTie/Seikagaku; VAP-1 antibody (rheumatoid arthritis/psoriasis), BioTie
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D06GUG

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Membrane copper amine oxidase (AOC3) TT7HC21 AOC3_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Membrane copper amine oxidase (AOC3) DTT AOC3 8.36E-22 -1.03 -1.54
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health.
2 Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.